logo
Plus   Neg
Share
Email

FDA Approves Amgen's Osteoporosis Drug Evenity

The U.S. Food and Drug Administration Tuesday approved Amgen Inc.'s (AMGN) Evenity for treatment of osteoporosis in postmenopausal women, who are at high risk of bone fractures.

More than 10 million people in the U.S. have osteoporosis, which is most common in women who have gone through menopause. People with osteoporosis have weakened bones that are more likely to fracture.

"Today's approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk," said Hylton Joffe, director of the Center for Drug Evaluation and Research's Division of Bone, Reproductive and Urologic Products.

However, Evenity increases the risk of cardiovascular death, heart attack and stroke in the alendronate trial, but not in the placebo trial. Evenity contains a boxed warning on its labeling stating that it may increase the risk of heart attack, stroke and cardiovascular death and should not be used in patients who have had a heart attack or stroke within the previous year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boeing (BA) will consider changing the name of the 737 MAX following its global grounding on safety concerns after two fatal crashes involving the jets in Ethiopia and Indonesia. Chief Financial Officer Greg Smith revealed this in an interview to Bloomberg on the sidelines of the Paris Air Show. He... Workers at Volkswagen AG's only factory in the U.S. have voted against forming a factory-wide union, dealing yet another blow to efforts by the United Auto Workers union to organize plants owned by foreign automakers. According to preliminary results announced on Friday, 833 workers at Volkswagen's plant in Chattanooga, Tennessee, reportedly voted against union representation. International Business Machines Corp. and Cúram Software, acquired by the tech giant in 2011, have agreed to pay $14.8 million to settle alleged violations of the False Claims Act, the Justice Department said in a statement. According to the DOJ, IBM and Cúram allegedly made material misrepresentations to the State of Maryland during a contract award process in 2011 and 2012.
Follow RTT